Tetrahydrofuran

Tetrahydrofuran

SCHEMBL2395526

C1CCOC1.CO.ClCCl

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
TTR P02766 1/20 0.31
TSHR P16473 1/20 0.31
PDK1 Q15118 1/20 0.31
PDK2 Q15119 1/20 0.31
PDK3 Q15120 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrahydrofuran SCHEMBL6732479 0.97 ALDH1A1 (0.50) ALDH1A1PDK1PDK2PDK3
Tetrahydrofuran SCHEMBL40243 0.89
Tetrahydrofuran SCHEMBL9077806 0.89 ALDH1A1 (0.67) ALDH1A1TTRTSHR
Tetrahydrofuran SCHEMBL10606207 0.88 ALDH1A1 (0.47) ALDH1A1TSHR
Cyclohexane SCHEMBL1742381 0.86 ALDH1A1 (0.61) ALDH1A1TTRTSHR
Methylene Chloride SCHEMBL537651 0.86 ALDH1A1 (0.61) ALDH1A1TTRTSHR
Tetrahydrofuran SCHEMBL6848959 0.86
Methylene Chloride SCHEMBL27973738 0.86
Tetrahydrofuran SCHEMBL1708038 0.86 ALDH1A1 (0.73) ALDH1A1TTRTSHRPDK1PDK2
Tetrahydrofuran SCHEMBL49157 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108558900-A A kind of derivative of nagilactone J and preparation method thereof and the application in mesenchymal stem cell culture 吾建峰 2018-09-21 CN claimed
CN-108530461-A A kind of derivative of nagilactone J and preparation method thereof and the purposes for promoting mesenchymal stem cells differentiation 吾建峰 2018-09-14 CN claimed
WO-2023088493-A1 FURO-PYRIDONE COMPOUND AND USE THEREOF 中国科学院广州生物医药与健康研究院 2023-05-25 WO disclosed
CN-108558900-A A kind of derivative of nagilactone J and preparation method thereof and the application in mesenchymal stem cell culture 吾建峰 2018-09-21 CN disclosed
CN-108530461-A A kind of derivative of nagilactone J and preparation method thereof and the purposes for promoting mesenchymal stem cells differentiation 吾建峰 2018-09-14 CN disclosed
US-8697692-B2 Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2014-04-15 US disclosed
US-8362251-B2 Pyrrolo [3,2-C] pyridine-4-one 2-indolinone protein kinase inhibitors SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2013-01-29 US disclosed
US-20110301353-A1 PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2011-12-08 US disclosed
US-8012966-B2 Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2011-09-06 US disclosed
CN-101039946-B Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogenesis and for the treatment of breast, colon, lung and prostate cancer HOFFMANN LA ROCHE 2010-12-08 CN disclosed
CN-101899049-A Disubstituted pyrazole and benzodiazepines class HOFFMANN LA ROCHE 2010-12-01 CN disclosed
US-20100004239-A1 Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2010-01-07 US disclosed
US-7524840-B2 7,8-disubstituted pyrazolobenzodiazepines HOFFMANN-LA ROCHE INC. (US) 2009-04-28 US disclosed
EP-1802625-B1 DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER HOFFMANN LA ROCHE (CH) 2008-06-18 EP disclosed
CN-101039946-A Disubstituted pyrazolobenzodiazepines * useful as inhibitors for CDK2 and angiogenesis and for the treatment of breast, colon, lung and prostate cancer HOFFMANN LA ROCHE (CH) 2007-09-19 CN disclosed
EP-1802625-A1 DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER F. Hoffmann-Roche AG (CH) 2007-07-04 EP disclosed
WO-2006040036-A1 DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER F. HOFFMANN-LA ROCHE AG (CH) 2006-04-20 WO disclosed
US-20060079511-A1 7,8-Disubstituted pyrazolobenzodiazepines LIU JIN-JUN 2006-04-13 US disclosed
US-5668271-A Indolopyrrolocarbazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-09-16 US disclosed
US-5135839-A Coupler mixture EASTMAN KODAK COMPANY (US) 1992-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301353-A1 PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS DMPK, PDPK1, PRKAR2A ALDH1A1 3032/4885TTR 4667/4885TSHR 1260/4885
US-20060079511-A1 7,8-Disubstituted pyrazolobenzodiazepines CDK2, CDK1, CDK7 ALDH1A1 2432/4885TTR 4866/4885TSHR 1618/4885
US-20100004239-A1 Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors DMPK, CDK2, PRKAR2A ALDH1A1 2899/4885TTR 4577/4885TSHR 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.